Technology may be advancing faster than people can keep up with but there are still times when traditional surgical methods are preferred over newer technologies.
While minimally invasive surgery is not a new concept the rapid advances in technology are helping to treat patients with more wide ranging conditions than ever before.
The FDA has granted approval for ustekinumab (Stelara/Janssen Biotech) to treat adults with moderately-to severely active Crohn’s disease (CD).
Panelists Peter L. Salgo, MD, and Joshua D. Lee, MD, PhD, discuss patient selection criteria for the use of long-acting naltrexone in the treatment of individuals with opioid dependency.
Peter L. Salgo, MD; Joshua D. Lee, MD, PhD; and Phillip Barbour discuss the mechanism of action for methadone and buprenorphine to prevent relapse in those who have a history of substance abuse.
Sirukumab, a rheumatoid arthritis treatment that has performed well in recent studies, is now awaiting approval in both the United States and Europe.
The FDA today approved its fourth biosimilar, a tumor necrosis factor inhibitor similar to adalimumab.
Peter A. McCullough, MD, and Nicolaas Deutz, MD, PhD, highlight the role of amino acids, protein, and B-hydroxy B-methylbutyrate in rebuilding muscle mass for patients with sarcopenia.
Nicolaas Deutz, MD, PhD, and Peter A. McCullough, MD, discuss the importance of the role of protein in treating malnutrition and sarcopenia.